Macquarie Group
VYNT

Macquarie Group’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Macquarie Group’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-26
Closed -$7K – 2434
2017
Q4 		$7K Buy
+26
New +$9.92K ﹤0.01% 2338

Other funds holding VYNT

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $160M AUM 14.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Macquarie Group's VYNT Position: Q1 2018 in Review

Macquarie Group sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2018, closing a stake of 26 shares — an estimated $7K sold.

Macquarie Group first reported a position in VYNT in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 26 funds tracked by Wall St. Rank hold VYNT as of Q1 2018.

  • Macquarie Group reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 26 Vyant Bio, Inc. Common Stock shares in Q1 2018, an estimated $7K.
  • Macquarie Group first reported a position in Vyant Bio, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Macquarie Group's Vyant Bio, Inc. Common Stock position peaked at $7K in Q4 2017.
  • 26 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.